Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.

"additional file 2 ). raw data"

"Declarations Ethics approval and consent to participateOral informed consent was obtained from all participants in the original SBII:2pre trial, which was approved by the ethical committees in Lund and Linköping, Sweden. Approval for the follow-up study and the genomic analyses was obtained (Dnr LU 2015/350, Dnr LU 2017/97). Biobank approval was obtained for all the pathology departments involved. Consent for publicationNot applicable. Competing interestsThe co-author, ME, has had a consultant/advisory role at Pfizer and Novartis. The co-author, SC, is an employee and shareholder of NanoString. Co-author MF has had a consultant/advisory role in Mavatar and has also contracted with PFS Genomics/Exact Sciences regarding genomic profiling and is a co-inventor of patent applications. The authors declare no conflicts of interest. Competing interests The co-author, ME, has had a consultant/advisory role at Pfizer and Novartis. The co-author, SC, is an employee and shareholder of NanoString. Co-author MF has had a consultant/advisory role in Mavatar and has also contracted with PFS Genomics/Exact Sciences regarding genomic profiling and is a co-inventor of patent applications. The authors declare no conflicts of interest."

"Funding Open access funding provided by Lund University. This study was supported by grants from the Swedish Cancer Society (Grant No. 19 0388Pj and 22 2137Pj), the Anna and Edwin Berger Foundation (Grants No. 2019-2022), the Governmental Funding of Clinical Research within the Swedish National Health Service (Grant No. 2022-40304), the Bertha Kamprad Foundation (Grant No. FBKS-2021-11), the Percy Falk Foundation, and Futurum—the Academy for Health and Care, Region Jönköping County."

"Trial registration This trial was retrospectively registered in the ISRCTN database the 6th of December 2019, trial ID: https://clinicaltrials.gov/ct2/show/ISRCTN12474687 ."